Evaluation of vilazodone for the treatment of depressive and anxiety disorders
| Autor: | Hugo Neels, Laurence Roosens, Erik J Giltay, Olivia Cools, Bernard Sabbe, Mirella Stuivenga |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Burden of disease
medicine.medical_specialty Serotonin reuptake inhibitor Vilazodone Hydrochloride 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine 5-HT1A receptor partial agonist mental disorders Vilazodone medicine anxiety disorder Animals Humans Pharmacology (medical) Psychiatry Pharmacology Depressive Disorder Major antidepressant major depressive disorder business.industry Pharmacology. Therapy serotonin reuptake inhibitor General Medicine medicine.disease Anxiety Disorders Antidepressive Agents chemistry vilazodone 030220 oncology & carcinogenesis Major depressive disorder Anxiety Antidepressant medicine.symptom business Selective Serotonin Reuptake Inhibitors 030217 neurology & neurosurgery Anxiety disorder |
| Zdroj: | Expert opinion on pharmacotherapy |
| ISSN: | 1744-7666 1465-6566 |
| DOI: | 10.1080/14656566.2018.1549542 |
| Popis: | Introduction: Major Depressive Disorder (MDD) and General Anxiety Disorder (GAD) significantly contribute to the global burden of disease. Vilazodone, a combined serotonin reuptake inhibitor and 5-HT1A partial agonist, is an approved therapy for the treatment of MDD and which has been further investigated for GAD. Areas covered: This article covers the pharmacokinetics and pharmacodynamics of vilazodone and provides an evaluation of the clinical usefulness of vilazodone for the treatment of MDD and anxiety disorders. A literature search was performed using PubMed/MEDLINE, Web of Science and the Cochrane Library. Expert opinion: Studies have shown that vilazodone is significantly superior to placebo. However, vilazodone cannot as yet be recommended as a first-line treatment option for MDD as it is unclear whether the drug's dual mechanism of action provides greater efficacy than prevailing treatment options. Moreover, more phase IV studies are needed to establish its efficacy and long-term safety in larger and more diverse populations. Although vilazodone may have an additional advantage for the treatment of anxiety symptoms in MDD, here also additional studies are required to confirm its efficacy over and above SSRI alternatives and other antidepressant treatments. Therefore, presently, vilazodone should be considered as a second- or third-line treatment option for MDD and GAD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|